Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Author(s): Alison C Tree, MDRes1,2; Peter Ostler, FRCR3; Hans van der Voet, MD4; William Chu, MD5; Andrew Loblaw, MD5; Daniel Ford, FRCR6; Shaun Tolan, MB BCh7; Prof Suneil Jain, PhD8; Alexander Martin, MDRes9; Prof John Staffurth, MD10; John Armstrong, FFRRCSI11,12; Philip Camilleri, FRCR13; Kiran Kancherla, FRCR14; John Frew, FRCR15; Andrew Chan, FRCR16; Ian S Dayes, MD17; Aileen Duffton, MSc18; Douglas H Brand, PhD1,2; Daniel Henderson, MDRes6; Kirsty Morrison, MDRes1,2; Stephanie Brown, PhD2; Julia Pugh, CIM Dip2; Stephanie Burnett, BSc2; Muneeb Mahmud, MSc2; Victoria Hinder, BSc1; Olivia Naismith, MSc1,19; Prof Emma Hall, PhD2; Prof Nicholas van As, MDRes1,2; on behalf of thePACE Trial Investigators
Author Affiliations
1The Royal Marsden Hospital, London, UK; 2The Institute of Cancer Research, London, UK; 3Mount Vernon Cancer Centre, Northwood, UK; 4The James Cook University Hospital, Middlesbrough, UK; 5Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 6University Hospitals Birmingham, Birmingham, UK; 7The Clatterbridge Cancer Centre, Liverpool, UK; 8Queen’s University Belfast, Belfast, UK; 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 10Cardiff University, Cardiff, UK; 11Cancer Trials Ireland, Dublin, Ireland; 12St Luke’s Radiation Oncology Network, St Lukes Hospital, Dublin, Ireland; 13Churchill Hospital, Oxford, UK; 14University Hospitals of Leicester, Leicester, UK; 15Freeman Hospital, Newcastle, UK; 16University Hospitals Coventry & Warwickshire, Coventry, UK; 17Department of Oncology, McMaster University, Hamilton, ON, Canada; 18Beatson West of Scotland Cancer Centre, Glasgow, UK; 19Radiotherapy Trials QA Group, London, UK